Overview

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of single agent TAK-573 in participants with relapsed/refractory MM in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-573 as a single agent and in combination with dexamethasone in participants with relapsed/refractory MM in Phase 2.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Dexamethasone